304 related articles for article (PubMed ID: 15210859)
1. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
An J; Rettig MB
Mol Cancer Ther; 2007 Jan; 6(1):61-9. PubMed ID: 17237266
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
5. NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Thapa RJ; Chen P; Cheung M; Nogusa S; Pei J; Peri S; Testa JR; Balachandran S
Mol Cancer Ther; 2013 Aug; 12(8):1568-78. PubMed ID: 23657944
[TBL] [Abstract][Full Text] [Related]
6. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
9. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
An J; Fisher M; Rettig MB
Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
[TBL] [Abstract][Full Text] [Related]
10. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
[TBL] [Abstract][Full Text] [Related]
12. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
15. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
19. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
